TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Share-based Compensation of $2.5 million for Q1 2026, down 27.8% year-over-year from $3.4 million in Q1 2025, and up 22.76% quarter-over-quarter from $2.0 million in Q4 2025.
TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Share-based Compensation for 7 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 27.8% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $10.8 million (down 2.02% YoY), while the FY2025 annual figure was $18.8 million, down 21.67% from the prior year.
- Share-based Compensation advanced to $2.5 million in Q1 2026 per TCRX's latest filing, from $2.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.4 million in Q1 2025 and bottomed at $984000.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $2.0 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 186.05% in 2022 and fell as far as 88.25% in 2022.
- TScan Therapeutics' Share-based Compensation stood at $1.3 million in 2022, then gained by 15.65% to $1.5 million in 2023, then jumped by 80.93% to $2.7 million in 2024, then dropped by 26.01% to $2.0 million in 2025, then gained by 22.76% to $2.5 million in 2026.
- Business Quant data shows TCRX's Share-based Compensation at $2.5 million in Q1 2026, $2.0 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 2.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.36 Mn |
| Jun 30, 2026 | 2.36 Mn |
| Mar 31, 2026 | 2.47 Mn |
| Mar 31, 2026 | 2.47 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Dec 31, 2025 | 2.01 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.98 Mn |